MedTrace Logo

Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis

NCT01766713 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-07-14

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).

Conditions

  • Non Alcoholic Steatohepatitis

Interventions

DRUG

Ezetimibe

10mg daily oral dose of ezetimibe

Sponsors & Collaborators

Principal Investigators

  • Rohit Loomba, MD, M.H.Sc · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-08-31
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01766713 on ClinicalTrials.gov